| Followers | 35 |
| Posts | 2799 |
| Boards Moderated | 0 |
| Alias Born | 10/28/2013 |
Friday, August 01, 2014 5:16:09 PM
More LP connections and positions (tentacles): Ran across these yesterday;
"Linda F. Powers is a co-founder and Managing Director of Toucan Capital, a $140 million venture capital fund based in Bethesda, MD. She has been appointed to key technology and industry commissions by the Governors of two states. Over the past 7 years, she has become a recognized leader in the stem cell industry nationwide in the U.S, as well as in Europe, India and China, and she served as the Chair of Maryland's Stem Cell Commission (responsible for administering the state's stem cell research funding) for the first two years of the program."
http://www.m2gen.com/who-we-are/board-of-directors/linda-powers
No date on the article.
"Linda F. Powers is a co-founder and Managing Director of Toucan Capital, a $140 million venture capital fund based in Bethesda, MD. She has been appointed to key technology and industry commissions by the Governors of two states. Over the past 7 years, she has become a recognized leader in the stem cell industry nationwide in the U.S, as well as in Europe, India and China, and she served as the Chair of Maryland's Stem Cell Commission (responsible for administering the state's stem cell research funding) for the first two years of the program."
http://www.m2gen.com/who-we-are/board-of-directors/linda-powers
No date on the article.
Recent NWBO News
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
